Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Simcere Pharmaceutical Group Limited (2096.HK)
Nanjing, CN
Simcere Pharmaceutical Group Limited is a Chinese entity engaged in the comprehensive process of discovering, developing, manufacturing, and commercializing pharmaceutical products. These medicines are distributed to various clients, including distributors, pharmacy chains, and fellow drug manufacturers within China. The company strategically focuses on a diverse range of therapeutic areas, notably oncology, central nervous system conditions, autoimmune diseases, anti-infective treatments, and cardiovascular health, among others. Its extensive product portfolio features key medications such as Sanbexin (an edaravone and dexborneol concentrated solution for injection), Endostar (a recombinant human endostatin injection), ENWEIDA (an envafolimab injection), Softan (rosuvastatin calcium tablets), ZAILIN (amoxicillin in granules, dispersible tablets, or capsules), Iremod (iguratimod tablets), Antine (diclofenac sodium sustained-release capsules or gel), and Orencia (an abatacept injection). Additionally, Simcere offers specialized promotional services for pharmaceutical goods. Demonstrating its commitment to innovation, the group has established a strategic regional licensing collaboration with Vivoryon Therapeutics N.V. This partnership aims to develop and commercialize novel therapies for Alzheimer's disease by targeting the neurotoxic amyloid protein N3pE (pGlu-Aß). Established in 1995, Simcere Pharmaceutical Group Limited is headquartered in Nanjing, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.15% | -4.32% | -15.79% | -19.60% | -26.91% | -16.71% | -22.35% | +27.01% | -7.51% | -9.20% | -9.20% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | +1 |
| Buy | 4 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+16.5% ★ Q4'25: +28.4% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+86.2% ★ Q4'25: +148.3% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%+20.6% ★ Q4'25: +20.1% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%+18.3% ★ Q4'25: +16.9% (vs Q4'23)
-
ROIC Biotechnology: -16.1%+18.0% ★ Q4'25: +34.9% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%-1.3% ★ Q4'25: -2.6% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.70× ★ Q4'25: 0.33× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 3 EPS Ana. |
Dec 2027 5 Rev. Ana. 3 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
4.51B
est: 5.44B (-17.1%)
|
5.00B
est: 6.26B (-20.2%)
|
6.32B
est: 7.08B (-10.8%)
|
6.61B
est: 5.90B (+12.1%)
|
6.64B
est: 6.67B (-0.5%)
|
7.73B
est: 7.65B (+1.1%)
|
10.25B
9.78B – 10.63B
+34.0% YoY
|
12.28B
11.04B – 13.35B
+19.8% YoY
|
14.25B
13.19B – 15.16B
+16.1% YoY
|
| EBITDA |
758.55M
est: 815.17M (-6.9%)
|
422.45M
est: 938.44M (-55.0%)
|
815.38M
est: 1.06B (-23.2%)
|
1.08B
est: 2.17B (-50.1%)
|
1.35B
est: 2.46B (-45.0%)
|
1.72B
est: 2.82B (-39.0%)
|
3.78B
3.60B – 3.92B
+34.0% YoY
|
4.52B
4.07B – 4.92B
+19.8% YoY
|
5.25B
4.86B – 5.58B
+16.1% YoY
|
| EBIT |
599.91M
est: 613.65M (-2.2%)
|
233.33M
est: 706.45M (-67.0%)
|
606.34M
est: 798.84M (-24.1%)
|
774.61M
est: 1.95B (-60.2%)
|
1.14B
est: 2.20B (-48.4%)
|
1.42B
est: 2.52B (-43.9%)
|
3.38B
3.23B – 3.51B
+34.0% YoY
|
4.05B
3.64B – 4.41B
+19.8% YoY
|
4.70B
4.35B – 5.00B
+16.1% YoY
|
| Net Income |
669.53M
est: 702.14M (-4.6%)
|
1.51B
est: 1.45B (+3.7%)
|
930.87M
est: 731.86M (+27.2%)
|
714.76M
est: -1.03B (+169.7%)
|
733.17M
est: 886.31M (-17.3%)
|
1.34B
est: 1.21B (+11.3%)
|
1.40B
1.35B – 2.35B
+15.8% YoY
|
2.05B
1.84B – 2.25B
+46.4% YoY
|
2.29B
2.20B – 2.38B
+12.1% YoY
|
| SGA |
1.98B
est: 2.46B (-19.4%)
|
2.42B
est: 2.83B (-14.6%)
|
2.85B
est: 3.20B (-11.1%)
|
2.84B
est: 2.68B (+6.0%)
|
3.03B
est: 3.04B (-0.2%)
|
3.51B
est: 3.48B (+0.9%)
|
4.67B
4.45B – 4.84B
+34.0% YoY
|
5.59B
5.02B – 6.07B
+19.8% YoY
|
6.49B
6.00B – 6.90B
+16.1% YoY
|
| EPS |
0.26
est: 0.28 (-6.7%)
|
0.58
est: 0.58 (+0.5%)
|
0.36
est: 0.29 (+25.9%)
|
0.27
est: -0.40 (+167.8%)
|
0.29
est: 0.36 (-19.2%)
|
0.54
est: 0.47 (+14.5%)
|
0.68
0.54 – 0.94
+44.2% YoY
|
0.82
0.74 – 0.90
+20.7% YoY
|
0.92
0.89 – 0.96
+12.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-30 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-29 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-28 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-27 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-24 | B+ | 3/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI China Small-Cap ETF ECNS | 0.88% | 569.6K | 0.59% |
| 2 | WisdomTree China ex-State-Owned Enterprises Fund CXSE | 0.13% | 623.9K | 0.32% |
| 3 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.12% | 87.9K | 0.74% |
| 4 | Avantis Emerging Markets Value ETF AVES | 0.11% | 1.65M | 0.36% |
| 5 | iShares Emerging Markets Equity Factor ETF EMGF | 0.11% | 2.10M | 0.26% |
| 6 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.11% | 131.7K | 0.42% |
| 7 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.08% | 511.7K | 0.55% |
| 8 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.08% | 311.0K | 0.72% |
| 9 | iShares MSCI EM Small Cap UCITS ETF IEMS.L | 0.08% | 279.1K | 0.74% |
| 10 | State Street SPDR S&P China ETF GXC | 0.05% | 226.2K | 0.59% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Renhong Tang | Executive Director | 11M | male |
| Jinsheng Ren | Co-Founder & Chairman | 9M | male |
| Yushan Wan | Chief Financial Officer, Joint Company Secretary & Executive Director | 7M | male |
| Xi Wang | Vice President & Executive Director | 2M | female |
| Wang Felix | Senior VP & Secretary of the Party Committee | — | — |
| Yongyu Wang | Senior Vice President & Chief Medical Officer of Simcere Zaiming | — | — |
| Yunshu Zhou | Chief Executive Officer | — | — |
| Tamas Oravecz | Senior Vice President & Chief Scientific Officer of Simcere Zaiming | — | — |
| Gaobo Zhou | Chief Investment Officer | — | male |
| Quanfu Feng | Vice President of Marketing | — | male |
| Aik Han Goh | Senior Vice President & Chief Medical Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2096.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
